Microbiome Therapeutics: Global Markets

Table of Contents

Chapter 1 Introduction

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

Chapter 2 Summary and Highlights

Key Highlights

Chapter 3 Market and Technology Background

The Human Microbiome

• The Different Microbiomes in Humans
• Microbiome and Human Health and Disease
• Technologies Aiding Microbiome Research
• Microbiome Research Projects

Microbiome Therapeutics

• Strategies for Development of Microbiome Therapeutics
• Microbiome Therapeutics Disease Areas
• Regulatory Landscape for Microbiome Therapeutics

Chapter 4 Market Breakdown by Technology Type

Market by Microbiome Strategy Type

• Market Overview
• Additive Microbiome Therapeutics
• Modulatory Microbiome Therapeutics
• Subtractive Microbiome Therapeutics

Chapter 5 Market Breakdown by Application

Market by Disease Type

• Market Overview
• Market Revenue
• Market Shares
• Infections
• Gastrointestinal (GIT) Diseases
• Metabolic Diseases
• Cancer
• Gut-Brain Axis Diseases
• Other Diseases

Market by Region

• Market Shares

Chapter 6 Industry Structure

Investment in Microbiome Therapeutics

• Public Funding Initiatives
• Private Funding Initiatives

Collaborations and Partnerships
Licensing and Manufacturing Agreements
Mergers and Acquisitions
Leading Market Players in Microbiome Therapeutics Market

• Leading Market Players in Additive Microbiome Therapeutics Market
• Leading Market Players in Modulatory Microbiome Therapeutics Market
• Leading Market Players in Subtractive Microbiome Therapeutics Market

BCC Research Select Insights from Industry Leaders

Chapter 7 Patent Analysis

Patent Analysis

• Patents by Year
• Patents by Type
• Patents by Disease Type
• Patents by Company
• Patents by Country
• Patents by Assignee

Chapter 8 Clinical Trial Analysis

Clinical Trial Analysis by Disease Category

• Share of Clinical Trials

Clinical Trial Analysis by Treatment Strategy

• Share of Clinical Trials

Clinical Trial Analysis by Company

• Share of Clinical Trials
• Microbiome Therapeutics in Discovery and Preclinical Development
• Microbiome Therapeutics Clinical Trials in Phase 3

Chapter 9 Analysis of Market Opportunities

SWOT Analysis

• Strengths of Microbiome Therapeutics Market
• Challenges for Microbiome Therapeutics Market
• Opportunities for Microbiome Therapeutics Market
• Threats to the Microbiome Therapeutics Market

Chapter 10 Company Profiles

4D PHARMA
AO BIOME LLC
ASSEMBLY BIOSCIENCES INC.
ARMATA PHARMACEUTICALS
AZITRA INC.
BIOMICA
BIOMX
CHAIN BIOTECHNOLOGY LTD.
ELIGO BIOSCIENCE SAS
ENTEROME SA
EVELO BIOSCIENCES
FINCH THERAPEUTICS GROUP INC.
INTRALYTIX INC.
KALEIDO BIOSCIENCES
KINTAI THERAPEUTICS INC.
LNC THERAPEUTICS INC.
MAAT PHARMA
OSEL INC.
PYLUM BIOSCIENES INC.
QUORUM INNOVATIONS LLC
REBIOTIX INC. (ACQUIRED BY FERRING PHARMACEUTICALS)
SECOND GENOME
SERES THERAPEUTICS INC.
SFA THERAPEUTICS INC.
SYNLOGIC
SYNTHETIC BIOLOGICS INC.
VEDANTA BIOSCIENCES INC.

Chapter 11 Appendix: Acronyms

List of Tables

Summary Table : Global Market for Microbiome Therapeutics, by Disease Type, Through 2026
Table 1 : Technologies for Microbiome Research
Table 2 : Dysbiosis in Microbiome
Table 3 : Leading Pharmaceuticals in Microbiome Therapeutics Partnerships
Table 4 : Global Market for Microbiome Therapeutics, by Strategy Type, Through 2026
Table 5 : Global Market Shares of Microbiome Therapeutics, by Strategy Type, 2024
Table 6 : LBPs in Microbiome Therapeutics
Table 7 : Global Market for Additive Microbiome Therapeutics, by Type, Through 2026
Table 8 : Global Market Shares of Additive Microbiome Therapeutics, by Type, 2024
Table 9 : Modulatory Microbiome Therapeutics
Table 10 : Global Market for Modulatory Microbiome Therapeutics, by Type, Through 2026
Table 11 : Global Market Shares of Modulatory Microbiome Therapeutics, by Type, 2024
Table 12 : Global Market for Subtractive Microbiome Therapeutics, by Type, Through 2026
Table 13 : Global Market Shares of Subtractive Microbiome Therapeutics, by Type, 2024
Table 14 : R&D Expenditures in Microbiome Therapeutics, by Company, 2017-2019
Table 15 : Global Market for Microbiome Therapeutics, by Disease Type, Through 2026
Table 16 : Global Market Shares of Microbiome Therapeutics, by Disease Type, 2024
Table 17 : Microbiome Therapeutics in Infections
Table 18 : Global Market for Microbiome Therapeutics for Infections, by Region, Through 2026
Table 19 : Microbiome Therapeutics in GIT Diseases
Table 20 : Global Market for Microbiome Therapeutics for GIT Diseases, by Region Through 2026
Table 21 : Microbiome Therapeutics in Metabolic Diseases
Table 22 : Global Market for Microbiome Therapeutics for Metabolic Diseases, by Region, Through 2026
Table 23 : Microbiome Therapeutics in Cancer
Table 24 : Global Market for Microbiome Therapeutics for Cancer, by Region, Through 2026
Table 25 : Microbiome Therapeutics in Gut-Brain Axis Diseases
Table 26 : Global Market for Microbiome Therapeutics for Gut-Brain Axis Diseases, by Region, Through 2026
Table 27 : Microbiome Therapeutics in Other Diseases
Table 28 : Global Market for Microbiome Therapeutics for Other Diseases, by Region, Through 2026
Table 29 : Global Market for Microbiome Therapeutics, by Region, Through 2026
Table 30 : Global Market Shares of Microbiome Therapeutics, by Region, 2024
Table 31 : Historical Funding Activity in Microbiome Therapeutics, 2015 and 2016
Table 32 : Public Funding in Microbiome Therapeutics, 2018-August 2020
Table 33 : Venture Funding in Microbiome Therapeutics, 2017-August 2020
Table 34 : Collaborations and Partnerships in the Microbiome Therapeutics Market, 2017-August 2020
Table 35 : Licensing and Manufacturing Agreements in the Microbiome Therapeutics Market, 2017-August 2020
Table 36 : Leading Developers of Additive Microbiome Therapeutics, 2019
Table 37 : Leading Developers of Modulatory Microbiome Therapeutics, 2019
Table 38 : Leading Developers of Subtractive Microbiome Therapeutics, 2019
Table 39 : Patents Issued for Microbiome Therapeutics, by Year, 2017-August 2020
Table 40 : Patents Issued for Microbiome Therapeutics, by Type, 2017-August 2020
Table 41 : Patents Issued for Microbiome Therapeutics, by Disease Type, 2017-August 2020
Table 42 : Patents Issued for Microbiome Therapeutics, by Company, 2017-August 2020
Table 43 : Patents Issued for Microbiome Therapeutics, by Country, 2017-August 2020
Table 44 : Patents Issued for Microbiome Therapeutics, by Assignee, 2017-August 2020
Table 45 : Clinical Trials in Microbiome Therapeutics, by Disease Type, August 2020
Table 46 : Share of Clinical Trials in Microbiome Therapeutics, by Disease Type, August 2020
Table 47 : Clinical Trials in Microbiome Therapeutics, by Treatment Strategy
Table 48 : Share of Clinical Trials in Microbiome Therapeutics, by Treatment Strategy
Table 49 : Clinical Trials in Microbiome Therapeutics, by Company
Table 50 : Share of Clinical Trials in Microbiome Therapeutics, by Top 10 Companies
Table 51 : Microbiome Therapeutics in Discovery and Preclinical Development
Table 52 : Microbiome Therapeutics Clinical Trials in Phase 3
Table 53 : 4D Pharma’s Pipeline
Table 54 : AO Biome’s Pipeline
Table 55 : Assembly Biosciences’ Pipeline
Table 56 : Armata Pharmaceuticals’ Pipeline
Table 57 : Azitra’s Pipeline
Table 58 : Biomica’s Pipeline
Table 59 : BiomX’s Pipeline
Table 60 : Chain Biotechnology’s Pipeline
Table 61 : Enterome’s Pipeline
Table 62 : Evelo Biosciences’ Pipeline
Table 63 : Finch Therapeutics’ Pipeline
Table 64 : Intralytix’s Pipeline
Table 65 : Kaleido Biosciences’ Pipeline
Table 66 : Kintai Therapeutics’ Pipeline
Table 67 : LNC Therapeutics’ Pipeline
Table 68 : MaaT Pharma’s Pipeline
Table 69 : Osel’s Pipeline
Table 70 : Quorum Innovations’ Pipeline
Table 71 : Rebiotix’s Pipeline
Table 72 : Second Genome’s Pipeline
Table 73 : Seres Therapeutics’ Pipeline
Table 74 : SFA Therapeutics’ Pipeline
Table 75 : Synlogic’s Pipeline
Table 76 : Synthetic Biologics’ Pipeline
Table 77 : Vedanta Biosciences’ Pipeline
Table 78 : Acronyms Used in Microbiome Therapeutics

List of Figures

Summary Figure : Global Market for Microbiome Therapeutics, by Disease Type, 2021-2026
Figure 1 : Differences in Human Genome and Microbiome
Figure 2 : Bacterial Distribution, by Body Site
Figure 3 : Essential Functions of Human Microbiome
Figure 4 : Dysbiosis and Human Health
Figure 5 : Summary of NIH Funding for Microbiome Research, 2012-2016
Figure 6 : Global Market for Microbiome Therapeutics, by Strategy Type, 2021-2026
Figure 7 : Global Market Shares of Microbiome Therapeutics, by Strategy Type, 2024
Figure 8 : Global Market for Additive Microbiome Therapeutics, by Type, 2021-2026
Figure 9 : Global Market Shares of Additive Microbiome Therapeutics, by Type, 2024
Figure 10 : Global Market for Modulatory Microbiome Therapeutics, by Type, 2021-2026
Figure 11 : Global Market Shares of Modulatory Microbiome Therapeutics, by Type, 2024
Figure 12 : Global Market for Subtractive Microbiome Therapeutics, by Type, 2021-2026
Figure 13 : Global Market Shares of Subtractive Microbiome Therapeutics, by Type, 2024
Figure 14 : Global Market for Microbiome Therapeutics, by Disease Type, 2021-2026
Figure 15 : Global Market Shares of Microbiome Therapeutics, by Disease Type, 2024
Figure 16 : Global Market for Microbiome Therapeutics for Infections, by Region, 2021-2026
Figure 17 : Global Market for Microbiome Therapeutics for GIT Diseases, by Region, 2021-2026
Figure 18 : Global Market for Microbiome Therapeutics for Metabolic Diseases, by Region, 2021-2026
Figure 19 : Global Market for Microbiome Therapeutics for Cancer, by Region, 2021-2026
Figure 20 : Global Market for Microbiome Therapeutics for Gut-Brain Axis Diseases, by Region, 2021-2026
Figure 21 : Global Market for Microbiome Therapeutics for Other Diseases, by Region, 2021-2026
Figure 22 : Global Market for Microbiome Therapeutics, by Region, 2021-2026
Figure 23 : Global Market Shares of Microbiome Therapeutics, by Region, 2024
Figure 24 : Patents Issued for Microbiome Therapeutics, by Year, 2017-August 2020
Figure 25 : Patents Issued for Microbiome Therapeutics, by Type, 2017-August 2020
Figure 26 : Patents Issued for Microbiome Therapeutics, by Disease Type, 2017-August 2020
Figure 27 : Patents Issued for Microbiome Therapeutics, by Company, 2017-August 2020
Figure 28 : Patents Issued for Microbiome Therapeutics, by Country, 2017-August 2020
Figure 29 : Patents Issued for Microbiome Therapeutics, by Assignee, 2017-August 2020
Figure 30 : Share of Clinical Trials in Microbiome Therapeutics, by Disease Type, August 2020
Figure 31 : Share of Clinical Trials in Microbiome Therapeutics, by Treatment Strategy
Figure 32 : Share of Clinical Trials in Microbiome Therapeutics, by Top 10 Companies
Figure 33 : SWOT Analysis of the Microbiome Therapeutics Market

当レポートのプレスリリースは発行されておりません。